Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for "Re-examination of New Drugs"
Phase of Trial: Phase IV
Latest Information Update: 25 May 2018
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HCV PMS
- Sponsors AbbVie
- 16 May 2018 Planned number of patients changed from 3000 to 1565.
- 12 Sep 2017 Status changed from not yet recruiting to recruiting.
- 30 Jun 2017 New trial record